Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Biofrontera ( (DE:B8FK) ) has issued an announcement.
Biofrontera AG announced that Biofrontera Inc. is facing payment difficulties, impacting the financial outlook for 2025. Despite an agreement to settle a two million Euro debt, uncertainties remain about Biofrontera Inc.’s ability to fulfill its obligations, potentially affecting Biofrontera AG’s operations and financial health. The situation has led to the withdrawal of previous financial forecasts, with the future viability of Biofrontera Inc. hinging on its ability to secure additional capital or alternative financing.
More about Biofrontera
Biofrontera AG is a company operating in the pharmaceutical industry, with subsidiaries Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH, collectively known as Biofrontera Germany. The company is involved in the development and commercialization of dermatological products, and it is listed on regulated markets in Dusseldorf and Frankfurt, as well as free markets in Berlin, Munich, Stuttgart, and Tradegate.
Average Trading Volume: 1,345
Technical Sentiment Signal: Sell
Current Market Cap: €16.04M
See more data about B8FK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue